What does this research mean for the field?

Iptacopan provides sustained hemolytic control, significant hemoglobin improvement, and favorable safety in complement inhibitor-naïve Chinese patients with paroxysmal nocturnal hemoglobinuria. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the real-world efficacy and safety of oral iptacopan in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria.

September 5, 2026Annals of HematologyOpen Access

Iptacopan treatment for chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): a multicenter retrospective study

View Full Paper

Ask AI

Bookmark

Authors

LWLeyu WangChinese Academy of Medical Sciences & Peking Union Medical College MZMin ZhangWuhan Union Hospital HCHong ChangSichuan University

Discussion

Member takes

Implication

Retrospective study demonstrates robust hemolytic control and high transfusion independence in paroxysmal nocturnal hemoglobinuria, indicating oral iptacopan offers strong real-world efficacy.

Key Points

To evaluate the real-world efficacy and safety of oral iptacopan in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria.
Conducted a multicenter retrospective study in China enrolling 54 complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (median age 38 years, range 21–82).
Evaluated clinical responses and laboratory parameters at 1, 3, and 6 months across a median follow-up of 10 months (range, 6–18 months).
Following treatment, 98.1% (53/54) of patients achieved lactate dehydrogenase levels ≤1.5 times the upper limit of normal, and 85.2% (46/54) reached hemoglobin levels ≥120 g/L.
All 20 baseline transfusion-dependent patients (100%) achieved transfusion independence, while breakthrough hemolysis occurred in 7.4% (4/54) of patients.
Adverse events included headache (13%) and upper respiratory tract infections (13%), with no reports of new thrombosis, extravascular hemolysis, or encapsulated bacterial infections.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4606b95aff0620ec16b https://doi.org/10.1007/s00277-026-07230-7

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study demonstrates robust hemolytic control and high transfusion independence in paroxysmal nocturnal hemoglobinuria, indicating oral iptacopan offers strong real-world efficacy.

Iptacopan treatment for chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): a multicenter retrospective study

Discussion

Member takes

Implication

Key Points

Cite This Study

Iptacopan treatment for chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): a multicenter retrospective study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider